Heplisav-B
Total Payments
$11.8M
Transactions
18,388
Doctors
10,204
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $446,227 | 5,747 | 3,773 |
| 2023 | $1.0M | 4,014 | 3,160 |
| 2022 | $2.5M | 3,407 | 2,546 |
| 2021 | $1.3M | 1,898 | 1,311 |
| 2020 | $4.0M | 891 | 494 |
| 2019 | $979,671 | 1,723 | 1,179 |
| 2018 | $1.5M | 708 | 618 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.7M | 735 | 82.3% |
| Consulting Fee | $1.6M | 420 | 13.8% |
| Food and Beverage | $328,273 | 17,197 | 2.8% |
| Current or prospective ownership or investment interest | $74,550 | 1 | 0.6% |
| Honoraria | $25,980 | 4 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,875 | 4 | 0.1% |
| Travel and Lodging | $11,750 | 25 | 0.1% |
| Grant | $3,916 | 1 | 0.0% |
| Education | $41.00 | 1 | 0.0% |
Payments by Type
Research
$9.7M
735 transactions
General
$2.1M
17,653 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Post-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B Compared with Another Hepatitis B Vaccine | Dynavax Technologies Corporation | $5.6M | 0 |
| HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis | Dynavax Technologies Corporation | $1.4M | 2 |
| Post-Marketing Observational Surveillance Study to Evaluate the Incidence of New-Onset Immune-Mediated Diseases, Herpes Zoster, and Anaphylaxis in Adults 18 Years of Age and Older Who Receive HEPLISAV B Compared with Another Hepatitis B Vaccine | Dynavax Technologies Corporation | $917,085 | 0 |
| HEPLISAV-B Pregnancy Registry: an observational study on the safety of HEPLISAV-B exposure in pregnant women and their offspring | Dynavax Technologies Corporation | $745,434 | 0 |
| Post-marketing Study for Immune-Mediated, Herpes Zoster, and Anaphylaxis Events | Dynavax Technologies Corporation | $509,714 | 0 |
| Heplisav-B Post Marketing Study - Immune-mediated Diseases, Hepes Zoster and Anaphylaxis | Dynavax Technologies Corporation | $404,979 | 0 |
| Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients | Dynavax Technologies Corporation | $39,144 | 0 |
| HEPLISAV-B Revaccination for Previous Hepatitis B Vaccine Non-Responders (In Veterans) | Dynavax Technologies Corporation | $14,053 | 0 |
| Immunologic Efficacy of HEPLISAV-B Vaccine in Patients Undergoing Treatment with Immunosuppressive Medications | Dynavax Technologies Corporation | $7,983 | 0 |
| Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders | Dynavax Technologies Corporation | $7,729 | 0 |
| Evaluating the impact of an adjuvanted vaccine (HEPLISAV-B) in healthcare personnel previously vaccinated using the standard 3-dose Hepatitis B vaccine who failed to demonstrate seroprotection | Dynavax Technologies Corporation | $3,900 | 0 |
| ost-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B Compared with Another Hepatitis B Vaccine | Dynavax Technologies Corporation | $1,000 | 0 |
Top Doctors Receiving Payments for Heplisav-B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $9.8M | 765 |
| , MD | Internal Medicine | Palo Alto, CA | $900,376 | 190 |
| , MD PHD | Research | Charlottesville, VA | $134,475 | 12 |
| , MD | Rheumatology | La Jolla, CA | $130,102 | 15 |
| , MD | Internal Medicine | New York, NY | $73,192 | 9 |
| , M.D | Contractor | Bethesda, MD | $62,100 | 43 |
| , MD | Nephrology | Philadelphia, PA | $53,609 | 12 |
| , M.D | Gastroenterology | Dallas, TX | $29,142 | 5 |
| , MD | Pediatrics | Marlboro, NJ | $25,500 | 3 |
| , MD | Pediatric Infectious Diseases | Chapel Hill, NC | $20,667 | 13 |
| , M.D | Internal Medicine | Rochester, MN | $20,125 | 8 |
| , M.D | Infectious Disease | Sylmar, CA | $17,612 | 18 |
| , M.D | Internal Medicine | Atlanta, GA | $15,606 | 8 |
| , MD | Pediatrics | Birmingham, AL | $15,490 | 7 |
| , MD | Pediatric Infectious Diseases | Aurora, CO | $14,325 | 12 |
| , M.D | Internal Medicine | Cincinnati, OH | $14,000 | 1 |
| , MD | Internal Medicine | Whittier, CA | $13,625 | 9 |
| , MD | Pediatrics | Pittsburgh, PA | $12,455 | 5 |
| , DO | Pediatrics | Tulsa, OK | $12,256 | 6 |
| , MD | Cardiovascular Disease | Dallas, TX | $11,750 | 10 |
| , MD | Internal Medicine | Phoenix, AZ | $10,010 | 1 |
| , M.D | Gastroenterology | Glendale, AZ | $7,847 | 3 |
| , MD | Pediatrics | Cleveland, OH | $6,600 | 2 |
| , MD | Infectious Disease | Atlanta, GA | $5,600 | 1 |
| , MD | Medical Oncology | Seattle, WA | $5,538 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $11.8M
- Total Doctors 10,204
- Transactions 18,388
About Heplisav-B
Heplisav-B is a drug associated with $11.8M in payments to 10,204 healthcare providers, recorded across 18,388 transactions in the CMS Open Payments database. The primary manufacturer is Dynavax Technologies Corporation.
Payment data is available from 2018 to 2024. In 2024, $446,227 was paid across 5,747 transactions to 3,773 doctors.
The most common payment nature for Heplisav-B is "Unspecified" ($9.7M, 82.3% of total).
Heplisav-B is associated with 12 research studies, including "Post-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B Compared with Another Hepatitis B Vaccine" ($5.6M).